2025
779-P: Cardiovascular Outcomes Associated with Dulaglutide, Exenatide, Liraglutide, and Semaglutide in Adults with Type 2 Diabetes at Moderate Cardiovascular Risk
SKLEPINSKI S, HERRIN J, SINDHU SWARNA K, NEUMILLER J, GALINDO R, UMPIERREZ G, ROSS J, DENG Y, POLLEY E, MARON B, MCCOY R. 779-P: Cardiovascular Outcomes Associated with Dulaglutide, Exenatide, Liraglutide, and Semaglutide in Adults with Type 2 Diabetes at Moderate Cardiovascular Risk. Diabetes 2025, 74 DOI: 10.2337/db25-779-p.Peer-Reviewed Original ResearchModerate CVD riskCVD riskType 2 diabetesCardiovascular diseaseAssociated with lower hazardRisk of cardiovascular outcomesCardiovascular disease outcomesCox proportional hazards modelsCardiovascular outcomesGlucagon-like peptide-1 receptor agonistsModerate cardiovascular riskCardiovascular risk reductionDigestive and Kidney DiseasesPeptide-1 receptor agonistsPropensity score inverse probabilityProportional hazards modelHazard of deathDepartment visitsNational Institute of DiabetesHazard of MACETrial emulationMedicare AdvantageMedicare plansComparative riskHazards model
2021
Prior Authorization, Copayments, and Utilization of Sacubitril/Valsartan in Medicare and Commercial Plans in Patients With Heart Failure With Reduced Ejection Fraction
Ozaki AF, Krumholz HM, Mody FV, Tran TT, Le QT, Yokota M, Jackevicius CA. Prior Authorization, Copayments, and Utilization of Sacubitril/Valsartan in Medicare and Commercial Plans in Patients With Heart Failure With Reduced Ejection Fraction. Circulation Cardiovascular Quality And Outcomes 2021, 14: e007665. PMID: 34465124, DOI: 10.1161/circoutcomes.120.007665.Peer-Reviewed Original ResearchConceptsSacubitril/valsartanSacubitril/valsartan useInsurance plan typeReduced ejection fractionHeart failureEjection fractionValsartan useCommercial plansNew York Heart Association classPA criteriaReduced ejection fraction patientsReduced ejection fraction populationPlan typeEjection fraction patientsMedicare plansEjection fraction populationCross-sectional studyProportion of plansPrescription copaymentsAssociation classCopayment amountPrimary outcomeClinical outcomesPlan populationMore prescriptions
2019
Budget Impact of Funding an Intensive Diet and Exercise Program for Overweight and Obese Patients With Knee Osteoarthritis
Smith KC, Losina E, Messier SP, Hunter DJ, Chen AT, Katz JN, Paltiel AD. Budget Impact of Funding an Intensive Diet and Exercise Program for Overweight and Obese Patients With Knee Osteoarthritis. ACR Open Rheumatology 2019, 2: 26-36. PMID: 31943972, PMCID: PMC6957917, DOI: 10.1002/acr2.11090.Peer-Reviewed Original ResearchKnee osteoarthritisMedicare plansIntensive dietKnee OA treatmentIncidence of comorbiditiesCommercial insurance plansHealth promotion interventionsMedicare-eligible individualsOsteoarthritis Policy ModelTotal knee replacementCommercial plansObese patientsOpioid useMore patientsExercise programArthritis trialsKnee replacementMedicare Advantage plansOsteoarthritisOA treatmentBudget impactMedical expendituresInsurance plansPatientsDiet
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply